These findings suggest that S100A9 serves as a common inflammatory marker for both diseases, whereas MYH2 may be regulated by disease-specific mechanisms, highlighting its potential for distinguishing COPD from NAFLD. This evidence concerns the gene S100A9 and metabolic dysfunction-associated steatotic liver disease.